Zhong Guo Jing Ji Wang·2026-02-25 01:35Group 1 - The company, Dongfang Biological, announced a projected net loss of 523 million yuan for the year 2025, with a net profit attributable to the parent company of -558 million yuan after excluding non-recurring gains and losses [1] - In 2024, Dongfang Biological reported an operating revenue of 828 million yuan, a year-on-year increase of 0.95%, but a net loss attributable to shareholders of -529 million yuan, compared to -398 million yuan in the previous year [1] - The net cash flow from operating activities for 2024 was -348 million yuan, an improvement from -1.646 billion yuan in the previous year [1] Group 2 - The total amount raised from the recent issuance by Dongfang Biological was 637.5 million yuan, with a net amount of 550.82 million yuan, which was 10.82 million yuan less than originally planned [2] - The company intended to use the raised funds for projects including the annual production of 24 million rapid diagnostic (POCT) products, the construction of a technology research and development center, marketing network and information management platform, and to supplement working capital [2] - The total issuance costs amounted to 86.68 million yuan, excluding value-added tax, with underwriting and sponsorship fees accounting for 60.60 million yuan [3]